Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Julia Kempf(LMU Klinikum), Karsten Spiekermann(German Cancer Research Center)

Scientific Reports

March 12, 2021

10.1038/s41598-021-84708-6

Cited by 48

Related Papers

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

|Leukemia|2017|339

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

|Journal of Clinical Oncology|2013|299

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

|Blood|2011|289

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

|Cancer Discovery|2021|282